Circulating endotoxin and interleukin-6 levels are associated with Doppler-evaluated pulmonary vascular resistance in cirrhotic patients

Hepatology International

Volumn 6, Issue 4, 2012, Pages 783-789

  Kalambokis, Georgios N ^a   Mouzaki, Athanasia ^a   Rodi, Maria ^b   Pappas, Konstantinos ^b   Korantzopoulos, Panagiotis ^a   Tsianos, Epameinondas V ^a,c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Cirrhosis; Endotoxin; Interleukin 6; Pulmonary hypertension

Indexed keywords

ENDOTOXIN; INTERLEUKIN 6;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; DISEASE ASSOCIATION; DOPPLER ECHOCARDIOGRAPHY; FEMALE; HEART OUTPUT; HEMODYNAMIC MONITORING; HUMAN; LIVER CIRRHOSIS; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SYSTEMIC VASCULAR RESISTANCE;

EID: 84874113007     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-011-9337-0     Document Type: Article

References (43)

1. Krowka MJ. Evolving dilemmas and management of portopulmonary hypertension. Semin Liver Dis 2006;26:265-272
2. Golbin JM, Krowka MJ. Portopulmonary hypertension. Clin Chest Med 2007;28:203-218
3. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004;363: 1461-1468
4. Scapellato F, Temporelli PL, Eleuteri E, et al. Accurate noninvasive estimation of pulmonary vascular resistance by Doppler echocardiography in patients with chronic heart failure. J Am Coll Cardiol 2001;37:1813-1819
5. Abbas AE, Fortuin FD, Schiller NB, et al. A simple method for noninvasive estimation of pulmonary vascular resistance. J Am Coll Cardiol 2003;41:1021-1027
6. Farzaneh-Far R, McKeown BH, Dang D, et al. Accuracy of Doppler-estimated pulmonary vascular resistance in patients before liver transplantation. Am J Cardiol 2008;101:259-262
7. Wong F, Moore K, Dingemanse J, et al. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. Hepatology 2008;47: 160-168
8. Wang YW, Lin HC, Yang YY, et al. Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertension. J Gastroenterol 2006;41:593-597
9. Garcia-Tsao G, Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004;18:353-372
10. Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral blood in patients with cirrhosis. Hepatology 1988;8:232-236
11. Deviere J, Content J, Denys C, et al. Excessive in vitro bacterial lipopolysaccharide-induced production of monokines in cirrhosis. Hepatology 1990;11:628-634
12. Han JH, Lee MY, Myung SC. The effect of endothelin-1 on the production of interleukin-6 in cultured human detrusor smooth muscle cells, and the effect of interleukin-6 on the contractile response of bladder smooth muscle strips from rats. BJU Int 2009;104:707-712
13. Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992;103:264-274
14. Westphal M, Daudel F, Bone HG, et al. New approach to an ovine model of hypodynamic endotoxaemia. Eur J Anaesthesiol 2004;21:625-631
15. Meyrick B, Brigham KL. Repeated Escherichia coli endotoxininduced pulmonary inflammation causes chronic pulmonary hypertension in sheep. Structural and functional changes. Lab Invest 1986;55:164-176
16. D'Orio V, Halleux J, Rodriguez LM, et al. Effects of Escherichia coli endotoxin on pulmonary vascular resistance in intact dogs. Crit Care Med 1986;14:802-806
17. Lambermont B, Kolth P, Detry O, et al. Analysis of endotoxin effects on the intact pulmonary circulation. Cardiovasc Res 1999;41:275-281
18. Rossi P, Persson B, Boels PJ, et al. Endotoxemic pulmonary hypertension is largely mediated by endothelin-induced venous constriction. Intensive Care Med 2008;34:873-880
19. Selimovic N, Bergh CH, Andersson B, et al. Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur Respir J 2009;34:662-668
20. Eddahibi S, Chaouat A, Tu L, et al. Interleukin-6 gene polymorphism confers susceptibility to pulmonary hypertension in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006;3:475-476
21. Chaouat A, Savale L, Chouaid C, et al. Role for interleukin-6 in COPD-related pulmonary hypertension. Chest 2009;136:678-687
22. Steiner MK, Syrkina OL, Kolliputi N, et al. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 2009;104: 236-244
23. Pellicelli AM, Barbaro G, Puoti C, et al. Plasma cytokines and portopulmonary hypertension in patients with cirrhosis waiting for orthotopic liver transplantation. Angiology 2010;61:802-806
24. Kalambokis GN, Mouzaki A, Rodi M, et al. Serum interleukin 6 levels and cirrhosis-associated pulmonary hypertension. Angiology 2011;62:344-345
25. British Thoracic Society. Guidelines for the measurement of respiratory function. Recommendations of the British Thoracic Society and the Association of Respiratory Technicians and Physiologists. Respir Med 1994;88:165-194
26. Schannwell CM, Steiner S, Strauer BE. Diagnostics in pulmonary hypertension. J Physiol Pharmacol 2007;58(Suppl 5):591-602
27. Himelman RB, StulbargM, KircherB, et al. Noninvasive evaluation of pulmonary artery pressure during exercise by saline-enhanced Doppler echocardiography in chronic pulmonary disease. Circulation 1989;79:863-871
28. Eakes AT, Howard KM, Miller JE, et al. Endothelin-1 production by hepatic endothelial cells: Characterization and augmentation by endotoxin exposure. Am J Physiol 1997;272:G605-G711
29. Dschietzig T, Alexiou K, Richter C, et al. Endotoxin causes pulmonary hypertension by upregulating smooth muscle endothelin type-B receptors: Role of aldose reductase. Shock 2008; 30:189-196
30. Wanecek M, Oldner A, Rudehill A, et al. Endothelin(A)-receptor antagonism attenuates pulmonary hypertension in porcine endotoxin shock. Eur Respir J 1999;13:145-151
31. Raij L. Glomerular thrombosis in pregnancy: Role of the L-arginine-nitric oxide pathway. Kidney Int 1994;45:775-781
32. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988;333:664-666.
33. Kishimoto T. The biology of interleukin-6. Blood 1989;74:1-10
34. Muller C, Zielinski CC. Interleukin-6 production by peripheral blood monocytes in patients with chronic liver disease and acute viral hepatitis. J Hepatol 1992;15:372-377
35. Yao JS, Zhai W, Fan Y, et al. Interleukin-6 upregulates expression of KDR and stimulates proliferation of human cerebrovascular smooth muscle cells. J Cereb Blood Flow Metab 2007; 27:510-520
36. Cool CD, Kennedy D, Voelkel NF, et al. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 1997;28:434-442
37. Myung SC, Han JH, Song KK, et al. The effects of interleukin-6 on the contraction and relaxation responses of the cavernous smooth muscle from rats. Eur J Pharmacol 2008;589:228-232
38. Miyata M, Ito M, Sasajima T, et al. Effect of serotonin receptor antagonist on interleukin-6-induced pulmonary hypertension in rats. Chest 2001;119:554-561
39. Lee FY, Lu RH, Tsai YT, et al. Plasma interleukin-6 levels in patients with cirrhosis. Relationship to endotoxemia, tumor necrosis factor-alpha, and hyperdynamic circulation. Scand J Gastroenterol 1996;31:500-505
40. Chu CJ, Lee FY, Wang SS, et al. Hyperdynamic circulation of cirrhotic rats with ascites: Role of endotoxin, tumor necrosis factor-alpha and nitric oxide. Clin Sci 1997;93:219-225
41. Zhang HY, de Han W, Su AR, et al. Intestinal endotoxemia plays a central role in development of hepatopulmonary syndrome in a cirrhotic rat model induced by multiple pathogenic factors. World J Gastroenterol 2007;13:6385-6395
42. Rabiller A, Nunes H, Lebrec D, et al. Prevention of gram-negative translocation reduces the severity of hepatopulmonary syndrome. Am J Respir Crit Care Med 2002;166:514-517
43. Gupta S, Faughnan ME, Lilly L, et al. Norfloxacin therapy for hepatopulmonary syndrome: A pilot randomized controlled trial. Clin Gastroenterol Hepatol 2010;8:1095-1098